1. Key Insights 2. Adrenoleukodystrophy Market Overview at a Glance 2.1. Market Share (%) Distribution of Adrenoleukodystrophy in 2016 2.2. Market Share (%) Distribution of Adrenoleukodystrophy in 2028 3. Disease Background and Overview: Adrenoleukodystrophy (ALD) 3.1. Introduction 3.2. Clinical aspects of ALD 3.3. Disease Causes 3.4. Inheritance pattern of ALD 3.5. ALD-Symptoms 3.6. Pathogenesis 3.7. ALD Diagnosis 3.8. X-ALD Newborn Screening 3.9. Tools for evaluating Cerebral X-ALD 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Disease Definition 4.3. Population and Forecast Parameters 5. 7MM Prevalent Population of Adrenoleukodystophy (ALD) 6. Country Wise-Epidemiology of Adrenoleukodystrophy (ALD) 6.1. United States 6.1.1. Prevalent Population of Adrenoleukodystrophy in United States 6.1.2. Diagnosed Prevalence of ALD by Clinical Manifestation in United States 6.1.3. Diagnosed Prevalence of CALD by Segmentation in United States 6.2. Germany 6.2.1. Prevalent Population of Adrenoleukodystrophy in Germany 6.2.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany 6.2.3. Diagnosed Prevalence of CALD by Segmentation in Germany 6.3. France 6.3.1. Prevalent Population of Adrenoleukodystrophy in France 6.3.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the France 6.3.3. Diagnosed Prevalence of CALD by Segmentation in France 6.4. Italy 6.4.1. Prevalent Population of Adrenoleukodystrophy in Italy 6.4.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy 6.4.3. Diagnosed Prevalence of CALD by Segmentation in Italy 6.5. Spain 6.5.1. Prevalent Population of Adrenoleukodystrophy in Spain 6.5.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain 6.5.3. Diagnosed Prevalence of CALD by Segmentation in Spain 6.6. United Kingdom 6.6.1. Prevalent Population of Adrenoleukodystrophy in United Kingdom 6.6.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the United Kingdom 6.6.3. Diagnosed Prevalence of CALD by Segmentation in United Kingdom 6.7. Japan 6.7.1. Prevalent Population of Adrenoleukodystrophy in Japan 6.7.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan 6.7.3. Diagnosed Prevalence of CALD by Segmentation in Japan 7. Current Treatment and Medical Practices 7.1. Subtype –Specific Treatment 7.2. Treatment Guidelines 7.3. Recommendations for Treatment of X-linked ALD in United States 7.4. Adrenoleukodystrophy treatment: European Leukodystrophies Association 7.5. Diagnostic and follow-up system for Adrenoleukodystrophy in Japan 8. Unmet Needs 9. Emerging Therapies 9.1. Key Cross Competition 10. Phase II/III Drugs 10.1. Lenti D: Bluebird Bio 10.1.1. Drug Description 10.1.2. Product Profile 10.1.3. Regulatory Milestones 10.1.4. Other Development Activities 10.1.5. Clinical Development 10.1.6. Clinical Trials Information 10.1.7. Safety and Efficacy 10.1.8. Advantages and Disadvantages 10.2. MIN-102: Minoryx Therapeutics, S.L. 10.2.1. Drug Description 10.2.2. Product Profile 10.2.3. Regulatory Milestones 10.2.4. Other Development Activities 10.2.5. Clinical Development 10.2.6. Clinical Trials Information 10.2.7. Safety and Efficacy 10.2.8. Advantages and Disadvantages 10.3. MD1003: MedDay Pharmaceuticals 10.3.1. Drug Description 10.3.2. Product Profile 10.3.3. Other Development Activities 10.3.4. Clinical Development 10.3.5. Clinical Trials Information 10.3.6. Safety and Efficacy 10.3.7. Advantages and Disadvantages 11. Phase I/II Drugs 11.1. NV1205: NeuroVia, Inc. 11.1.1. Drug Description 11.1.2. Product Profile 11.1.3. Other Development Activities 11.1.4. Clinical Development 11.1.5. Clinical Trials Information 11.1.6. Safety and Efficacy 11.1.7. Advantages and Disadvantages 11.2. OP-101: Orpheris Inc. 11.3. Drug Description 11.4. Product Profile 11.5. Regulatory Milestones 11.6. Other Development Activities 11.7. Clinical Development 12. Adrenoleukodystrophy (ALD): Market Analysis 12.1. Key Findings 12.2. Assumptions and Forecasting Parameters 12.3. Key Events and Impacts 13. Adrenoleukodystrophy (ALD): Total Market Size in 7MM 13.1. Total Market Size of ALD in 7MM 13.2. Market size of ALD by Segmentation in 7MM 13.3. Therapy-based Market Size of ALD in 7MM 13.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in 7MM 13.5. Market size of CALD by Segmentation in 7MM 13.6. Therapy-based Market size of CALD in 7MM 14. Market Size of Adrenoleukodystrophy (ALD) by Country 14.1. United States Market Analysis 14.1.1. Market Size of ALD in the U.S. 14.1.2. Market size of ALD by Segmentation in the U.S. 14.1.3. Therapy-based Market Size of ALD in the U.S. 14.1.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in the U.S. 14.1.5. Market size of CALD by Segmentation in the U.S. 14.1.6. Therapy-based Market size of CALD in the U.S. 14.2. EU-5: Market Analysis 14.3. Germany 14.3.1. Market Size of ALD in the Germany 14.3.2. Market size of ALD by Segmentation in Germany 14.3.3. Therapy-based Market Size of ALD in Germany 14.3.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in Germany 14.3.5. Market size of CALD by Segmentation in Germany 14.3.6. Therapy-based Market size of CALD in Germany 14.4. France 14.4.1. Market Size of ALD in France 14.4.2. Market size of ALD by Segmentation in France 14.4.3. Therapy-based Market Size of ALD in France 14.4.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in France 14.4.5. Market size of CALD by Segmentation in France 14.4.6. Therapy-based Market size of CALD in France 14.5. Italy 14.5.1. Market Size of ALD in Italy 14.5.2. Market size of ALD by Segmentation in Italy 14.5.3. Therapy-based Market Size of ALD in Italy 14.5.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in Italy 14.5.5. Market size of CALD by Segmentation in Italy 14.5.6. Therapy-based Market size of CALD in Italy 14.6. Spain 14.6.1. Market Size of ALD in Spain 14.6.2. Market size of ALD by Segmentation in Spain 14.6.3. Therapy-based Market Size of ALD in Spain 14.6.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in Spain 14.6.5. Market size of CALD by Segmentation in Spain 14.6.6. Therapy-based Market size of CALD in Spain 15. Japan: Market Analysis 15.1. Market Size of ALD in Japan 15.2. Market size of ALD by Segmentation in Japan 15.3. Market size of Cerebral Adrenoleukodystrophy [CALD] in Japan 16. Market Drivers 17. Market Barriers 18. Appendix 19. Report Methodology 19.1. Sources used 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight

Table 1: X-ALD Phenotypes in Males Table 2: Phenotype in Female X-ALD carriers Table 3: The X-ALD Phenotypes Table 4: MRI Severity Scale Table 5: MRI Severity Rating (Loes Score) Table 6: Neurological Function Score (NFS Score) Table 7: X-linked Adrenoleukodystrophy- Disability Rating Scale (ALD-DRS) Table 8: Prevalent Population of Adrenoleukodystophy in the 7MM (2016-2028) Table 9: Prevalent Population of Adrenoleukodystrophy in United States (2016-2028) Table 10: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2028) Table 11: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2028) Table 12: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2028) Table 13: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2028) Table 14: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2028) Table 15: Prevalent Population of Adrenoleukodystrophy in France (2016-2028) Table 16: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2028) Table 17: Diagnosed Prevalence of CALD by Segmentation in France (2016-2028) Table 18: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2028) Table 19: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2028) Table 20: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2028) Table 21: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2028) Table 22: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2028) Table 23: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2028) Table 24: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2028) Table 25: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2028) Table 26: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2028) Table 27: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2028) Table 28: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2028) Table 29: Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2028) Table 30: X-linked Adrenoleukodystrophy Phenotypes Treatment Table 31: Recommendations for Addison Disease Table 32: Hormonal therapies for Addison Disease Table 33: Adrenoleukodystrophy treatment Table 34: Adrenoleukodystrophy treatment Table 35: Phase II/III Drug analysis Table 36: Phase I/II/III Drug analysis Table 37: Lenti D, Clinical Trial Description, 2016 Table 38: MIN-102, Clinical Trial Description, 2016 Table 39: MD1003, Clinical Trial Description, 2016 Table 40: NV1205, Clinical Trial Description, 2016 Table 41: Forecasting parameters and assumptions for Market Forecast in 7MM (2016-2028) Table 42: 7MM Major Market Size of ALD in USD Million (2016-2028) Table 43: Market Size of ALD by Segmentation in 7MM in USD Million (2016-2028) Table 44: Therapy Based US Market Size of CALD in USD Million (2016-2028) Table 45: Market Size of CALD in 7MM in USD Million (2016-2028) Table 46: Market Size of CALD by Segmentation in 7MM in USD Million (2016-2028) Table 47: 7MM Therapy Based Market Size of CALD in USD Million (2016-2028) Table 48: U.S. Market Size of ALD in USD Million (2016-2028) Table 49: U.S. Market Size of ALD by Segmentation in USD Million (2016-2028) Table 50: Therapy Based US Market Size of ALD in USD Million (2016-2028) Table 51: U.S. Market Size of CALD in USD Million (2016-2028) Table 52: U.S. Market Size of CALD by Segmentation in USD Million (2016-2028) Table 53: Therapy Based US Market Size of CALD in USD Million (2016-2028) Table 54: Germany Market Size of ALD in USD Million (2016-2028) Table 55: Germany Market Size of ALD by Segmentation in USD Million (2016-2028) Table 56: Therapy Based Germany Market Size of ALD in USD Million (2016-2028) Table 57: Germany Market Size of CALD in USD Million (2016-2028) Table 58: Germany Market Size of CALD by Segmentation in USD Million (2016-2028) Table 59: Therapy Based Germany Market Size of CALD in USD Million (2016-2028) Table 60: France Market Size of ALD in USD Million (2016-2028) Table 61: France Market Size of ALD by Segmentation in USD Million (2016-2028) Table 62: Therapy Based France Market Size of ALD in USD Million (2016-2028) Table 63: France Market Size of CALD in USD Million (2016-2028) Table 64: France Market Size of CALD by Segmentation in USD Million (2016-2028) Table 65: Therapy Based France Market Size of CALD in USD Million (2016-2028) Table 66: Italy Market Size of ALD in USD Million (2016-2028) Table 67: Italy Market Size of ALD by Segmentation in USD Million (2016-2028) Table 68: Therapy Based Italy Market Size of ALD in USD Million (2016-2028) Table 69: Italy Market Size of CALD in USD Million (2016-2028) Table 70: Italy Market Size of CALD by Segmentation in USD Million (2016-2028) Table 71: Therapy Based Italy Market Size of CALD in USD Million (2016-2028) Table 72: Spain Market Size of ALD in USD Million (2016-2028) Table 73: Spain Market Size of ALD by Segmentation in USD Million (2016-2028) Table 74: Therapy Based Italy Market Size of ALD in USD Million (2016-2028) Table 75: Spain Market Size of CALD in USD Million (2016-2028) Table 76: Spain Market Size of CALD by Segmentation in USD Million (2016-2028) Table 77: Therapy Based Italy Market Size of CALD in USD Million (2016-2028) Table 78: Japan Market Size of ALD in USD Million (2016-2028) Table 79: Spain Market Size of ALD by Segmentation in USD Million (2016-2028) Table 80: Japan Market Size of CALD in USD Million (2016-2028) Figure 1: Evolution of Phenotypes in X-ALD Figure 2: Clinical Spectrum of X-ALD Figure 3: Inheritance spectrum of X-ALD Figure 4: Pathogenesis of VLCFA Figure 5: Principles of ALD 3-tier screening Figure 6: Diagnostic algorithm for diagnosis of adrenoleukodystrophy Figure 7: Prevalent Population of X-Adrenoleukodystophy in the 7MM (2016-2028) Figure 8: Prevalent Population of Adrenoleukodystrophy in United States (2016-2028) Figure 9: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2028) Figure 10: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2028) Figure 11: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2028) Figure 12: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2028) Figure 13: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2028) Figure 14: Prevalent Population of Adrenoleukodystrophy in France (2016-2028) Figure 15: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2028) Figure 16: Diagnosed Prevalence of CALD by Segmentation in France (2016-2028) Figure 17: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2028) Figure 18: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2028) Figure 19: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2028) Figure 20: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2028) Figure 21: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2028) Figure 22: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2028) Figure 23: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2028) Figure 24: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2028) Figure 25: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2028) Figure 26: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2028) Figure 27: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2028) Figure 28 Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2028) Figure 29: Treatment General Practices Figure 30: Out-patient management of X-ALD Figure 31: Follow-up for pre-symptomatic ALD Figure 32: Unmet Needs of Adrenoleukodystrophy Figure 33: 7 Major Market Size of ALD in USD Million (2016-2028) Figure 34: Market Size of ALD by Segmentation in 7MM in USD Million (2016-2028) Figure 35: 7MM Therapy Based Market Size of ALD in USD Million (2016-2028) Figure 36: Market Size of CALD in 7MM in USD Million (2016-2028) Figure 37: Market Size of CALD by Segmentation in 7MM in USD Million (2016-2028) Figure 38: 7MM Therapy Based Market Size of CALD in USD Million (2016-2028) Figure 39: U.S. Market Size of ALD in USD Million (2016-2028) Figure 40: US Market Size of ALD by Segmentation in USD Million (2016-2028) Figure 41: Therapy Based US Market Size of ALD in USD Million (2016-2028) Figure 42: U.S. Market Size of CALD in USD Million (2016-2028) Figure 43: U.S. Market Size of CALD by Segmentation in USD Million (2016-2028) Figure 44: Therapy Based US Market Size of CALD in USD Million (2016-2028) Figure 45: Germany Market Size of ALD in USD Million (2016-2028) Figure 46: Germany Market Size of ALD by Segmentation in USD Million (2016-2028) Figure 47: Therapy Based Germany Market Size of ALD in USD Million (2016-2028) Figure 48: Germany Market Size of CALD in USD Million (2016-2028) Figure 49: Germany Market Size of CALD by Segmentation in USD Million (2016-2028) Figure 50: Therapy Based Germany Market Size of CALD in USD Million (2016-2028) Figure 51: France Market Size of ALD in USD Million (2016-2028) Figure 52: France Market Size of ALD by Segmentation in USD Million (2016-2028) Figure 53: Therapy Based France Market Size of ALD in USD Million (2016-2028) Figure 54: France Market Size of CALD in USD Million (2016-2028) Figure 55: France Market Size of CALD by Segmentation in USD Million (2016-2028) Figure 56: Therapy Based France Market Size of CALD in USD Million (2016-2028) Figure 57: Italy Market Size of ALD in USD Million (2016-2028) Figure 58: Italy Market Size of ALD by Segmentation in USD Million (2016-2028) Figure 59: Therapy Based Italy Market Size of ALD in USD Million (2016-2028) Figure 60: Italy Market Size of CALD in USD Million (2016-2028) Figure 61: Italy Market Size of CALD by Segmentation in USD Million (2016-2028) Figure 62: Therapy Based Italy Market Size of CALD in USD Million (2016-2028) Figure 63: Spain Market Size of ALD in USD Million (2016-2028) Figure 64: Spain Market Size of ALD by Segmentation in USD Million (2016-2028) Figure 65: Therapy Based Spain Market Size of ALD in USD Million (2016-2028) Figure 66: Spain Market Size of CALD in USD Million (2016-2028) Figure 67: Spain Market Size of CALD by Segmentation in USD Million (2016-2028) Figure 68: Therapy Based Spain Market Size of CALD in USD Million (2016-2028) Figure 69: Japan Market Size of ALD in USD Million (2016-2028) Figure 70: Japan Market Size of ALD by Segmentation in USD Million (2016-2028) Figure 71: Japan Market Size of CALD in USD Million (2016-2028) Figure 72: Market Drivers Figure 73: Market Barriers